Cancer patients had a lower proportion of CD3+ cells than healthy individuals (45.54%/55.83%, P <0.0001), but a higher proportion of CD14+/CD3-CD56+CD16+ cells (30.04%/15.17%, P <0.0001 versus 17.45%/14.93%, P =0.0037). Here, CD14 is linked to cancer.